再鼎医药(09688)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09688 再鼎医药

未开盘 12-15 16:08:35

13.780

-0.520

-3.64%

最高14.160	最低13.730	成交量899.13万
今开13.920	昨收14.300	日振幅3.01%
总市值154.34亿	流通市值154.34亿	总股本11.20亿
成交额1.25亿	换手率0.80%	流通股本11.20亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09688","market":"HK","secType":"STK","nameCN":"再鼎医药","latestPrice":13.78,"timestamp":1765786115011,"preClose":14.3,"halted":0,"volume":8991320,"delay":0,"floatShares":1120000000,"shares":1120000000,"eps":-2.0220463494731598,"marketStatus":"未开盘","change":-0.52,"latestTime":"12-15 16:08:35","open":13.92,"high":14.16,"low":13.73,"amount":125073486,"amplitude":0.03007,"askPrice":13.78,"askSize":214000,"bidPrice":13.77,"bidSize":1700,"shortable":3,"etf":0,"ttmEps":-1.4963735972980967,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765848600000},"marketStatusCode":0,"adr":0,"listingDate":1601222400000,"exchange":"SEHK","adjPreClose":14.3,"openAndCloseTimeList":[[1765762200000,1765771200000],[1765774800000,1765785600000]],"volumeRatio":0.777199,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09688","defaultTab":"news","newsList":[{"id":"2590233595","title":"【券商聚焦】交银国际：创新药增量支付空间持续扩大","url":"https://stock-news.laohu8.com/highlight/detail?id=2590233595","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590233595?lang=zh_cn&edition=full","pubTime":"2025-12-12 09:02","pubTimestamp":1765501348,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际表示，10月以来，内资通过港股通持有医药股的比例小幅下降，外资持仓整体平稳，内外资加大创新药布局的大方向不变。该机构指，本周医保+商保双目录落地，医保谈判新增品种成功率创近年新高，续约品种降价幅度相对温和。该机构认为商保资金的引入将为创新药支付带来重要增量资金，进一步优化多元支付体系。该机构看好医保新纳入品种/适应症在2026年的销售放量，以及首版商保目录的实际执行和支付情况。","market":"us","thumbnail":"https://static.szfiu.com/news/20250109/M2QyMTYxN2UxNmI4NDk2OTg5NThlNDVhNTUzNjZhZTcxMjcxMzE0NDc4MDA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/M2QyMTYxN2UxNmI4NDk2OTg5NThlNDVhNTUzNjZhZTcxMjcxMzE0NDc4MDA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1971425","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999002463.SGD","159992","LU1951186391.HKD","LU0043850808.USD","LU2778985437.USD","HK0000165453.HKD","LU0181495838.USD","LU0516423091.SGD","LU0067412154.USD","LU2097828557.USD","LU0502904849.HKD","LU1226287529.USD","LU0359201612.USD","LU0634319403.HKD","LU1961090484.USD","01801","02142","LU0708995583.HKD","02616","LU0417516738.SGD","BK1161","01877","LU0359202008.SGD","09995","02269","LU1993786604.SGD","LU1969619763.USD","SG9999004220.SGD","01093","LU0540923850.HKD","LU0880133367.SGD","LU2039709279.SGD","BK1588","LU1770034418.SGD","06160","LU0348766576.USD","01177","06185","LU2097828714.EUR","03329","09688","LU2097828631.EUR","LU0456827905.SGD","LU2242644610.SGD","09926","LU2328871848.SGD","IE00B0JY6N72.USD","LU1794554557.SGD","06978","LU1242518931.SGD"],"gpt_icon":0},{"id":"2590277595","title":"智通港股52周新高、新低统计|12月11日","url":"https://stock-news.laohu8.com/highlight/detail?id=2590277595","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590277595?lang=zh_cn&edition=full","pubTime":"2025-12-11 16:40","pubTimestamp":1765442401,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，截止12月11日收盘，有28只股票创52周新高，其中亚洲富思、圆美光电、瑞丽医美创高率位于前3位，分别为88.24%、30.43%、22.50%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380369.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02231","02431","01157","00296","01239","03288","00145","02210","02888","00204","02693","02562","02621","01709","00493","02135","06980","01341","01539","01790","02023","00014","02609","00701","01937","01855","00551","02582","01304","02367","02378","01176","00038","00005","01965","00325","02556","06960","09869","00632","01758","01274","09688","00139","03692","00341","01047","00917","02699"],"gpt_icon":1},{"id":"2590598819","title":"每日卖空追踪 | 再鼎医药 12月10日卖空量成交174.54万股，卖空比例为12.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590598819","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590598819?lang=zh_cn&edition=full","pubTime":"2025-12-10 16:30","pubTimestamp":1765355441,"startTime":"0","endTime":"0","summary":"再鼎医药北京时间12月10日，跌4.42%，卖空量成交174.54万股，较上一交易日减少13.9%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251210163838a72f510e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251210163838a72f510e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1588","LU2488822045.USD","09688","BK1574"],"gpt_icon":0},{"id":"1102748254","title":"港股创新药概念股盘初普跌！歌礼制药-B跌近6%、金斯瑞生物科技跌近5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1102748254","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102748254?lang=zh_cn&edition=full","pubTime":"2025-12-10 09:44","pubTimestamp":1765331074,"startTime":"0","endTime":"0","summary":"12月10日，港股创新药概念股盘初普跌，$歌礼制药-B(01672)$跌近6%，$金斯瑞生物科技(01548)$跌近5%，$再鼎医药(09688)$跌超3%，$康方生物(09926)$、$药明康德(00013)$、$药明生物(02269)$跌超2%.","market":"hk","thumbnail":"https://static.tigerbbs.com/c7da52addfd52fb216bcf87283f43750","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/c7da52addfd52fb216bcf87283f43750"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"41fbc90a42b871f5da0d5addc6c1afd7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BPRC5H50.USD","LU0516422440.USD","LU0326950275.SGD","LU1794554557.SGD","BK1589","LU0516422952.EUR","LU1688375341.USD","ZLAB","01548","01672","BK1610","LU0588546209.SGD","LU2476274720.SGD","LU1880383366.USD","06978","IE00B543WZ88.USD","LU0348766576.USD","LU0516422366.SGD","LU0052750758.USD","09926","LU0572944931.SGD","LU0320764599.SGD","LU0348735423.USD","HK0000306685.HKD","SG9999002562.SGD","BK1574","BK4585","BK1583","BK4139","BK1141","LU0456846285.SGD","LU0348767384.USD","LU0634319403.HKD","LU0516423174.USD","LU0561508036.HKD","LU0181495838.USD","BK1161","LU2488822045.USD","BK1515","HK0000306701.USD","SG9999002463.SGD","IE00B0JY6N72.USD","LU0359201612.USD","BK4548","LU0417516902.SGD","LU0307460666.USD","LU0359202008.SGD","HK0000320223.HKD","LU2039709279.SGD","LU0348825331.USD","LU1242518857.USD","LU0051755006.USD","LU0708995583.HKD","LU1720050803.USD","BK1576","BK4531","LU0039217434.USD","09688","LU0823426480.USD","LU0348827113.USD","IE00B5MMRT66.SGD","02269","LU0819121731.USD","01477","LU0140636845.USD","LU0979878070.USD","BK1588","LU2778985437.USD","LU0417516571.SGD","LU0823426308.USD","LU3063872942.SGD","LU0856984785.SGD","LU0043850808.USD","LU0327786744.USD","LU0348784397.USD","LU1961090484.USD","HK0000320264.USD","LU1242518931.SGD","BK1521","BK4526","LU0417516738.SGD","LU0456827905.SGD","BK4588","LU0540923850.HKD","LU2476274308.USD","LU0516423091.SGD","LU0348783233.USD","LU2399975544.HKD"],"gpt_icon":0},{"id":"2590367035","title":"【券商聚焦】交银国际：2025年医保+商保双目录落地 多元支付体系盘活创新药增量空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2590367035","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590367035?lang=zh_cn&edition=full","pubTime":"2025-12-09 08:59","pubTimestamp":1765241994,"startTime":"0","endTime":"0","summary":"调整后的目录中，药品总数增至3,253种。新版目录将于2026年1月1日正式实施。该机构认为，更多新药进入目录有助于提升临床用药水平，及创新药行业整体研发回报率；商保资金的引入将为创新药支付带来重要增量资金，为多元化支付体系的建立奠定基础。百济有两款产品纳入商保创新药目录，信达、和黄各有一款纳入。同时重点关注首批商保目录的实际执行和支付情况、名单及定价的动态调整以及真实世界数据积累带来的长期发展机会。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250109/MjdmY2Y4OTEwODUyNTc5NjI3Mg==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjdmY2Y4OTEwODUyNTc5NjI3Mg==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1971149","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0572944931.SGD","LU0327786744.USD","LU0140636845.USD","LU1951186391.HKD","LU0348767384.USD","BK1588","02616","159992","LU0708995583.HKD","LU1720050803.USD","01877","LU1770034418.SGD","BK1161","LU0456827905.SGD","02142","06160","06978","LU1226288170.HKD","LU0348766576.USD","LU2399975544.HKD","02269","LU1813983027.USD","01801","BK1576","LU0348783233.USD","LU1969619763.USD","BK1574","BK1610","LU0181495838.USD","LU0348784397.USD","BK1141","IE00B0JY6N72.USD","LU0880133367.SGD","BK1147","IE00B543WZ88.USD","09926","LU2039709279.SGD","01177","IE00BZ08YR35.GBP","LU0516423091.SGD","LU0417516902.SGD","LU1719994722.HKD","LU2476274308.USD","09688","LU0326950275.SGD","01093","06185","BK1191","03329","09995"],"gpt_icon":0},{"id":"1117272123","title":"再鼎医药在全球1/1B期研究中为Zl-1503（IL-13/IL-31R双特异性抗体）首名参与者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1117272123","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117272123?lang=zh_cn&edition=full","pubTime":"2025-12-08 20:03","pubTimestamp":1765195436,"startTime":"0","endTime":"0","summary":"再鼎医药在全球1/1B期研究中为Zl-1503（IL-13/IL-31R双特异性抗体）首名参与者给药","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","BK1161","BK1588","BK1574","09688"],"gpt_icon":0},{"id":"2589380386","title":"80%、50种，我国医保目录成为创新药快速落地“加速器”","url":"https://stock-news.laohu8.com/highlight/detail?id=2589380386","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589380386?lang=zh_cn&edition=full","pubTime":"2025-12-07 23:22","pubTimestamp":1765120920,"startTime":"0","endTime":"0","summary":"我国已建立每年一调的医保目录动态调整机制，聚焦5年内新上市药品。2025年新纳入的114种药品中，多个实现当年获批上市即进目录。2018年以来，我国1类创新药获批数量明显上升，2024年达48种，医保目录成其快速落地“加速器”，推动市场扩容。药企研发投入有稳定回报预期，将激励更多药企加大创新研发，尤其针对肿瘤、罕见病等未满足需求领域。新药从获批到纳入医保报销的时间从5年缩短至1年左右，约80%的创新药能在上市两年内进目录。医保准入成市场拓展关键，通过“腾笼换鸟”优化资源配置，推动医药行业向高质量、创新型转型。目前，2025年国家医保药品目录内药品总数达3253种，1类创新药增至50种。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512072346299794c403&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512072346299794c403&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06978","09926","06160","09995","09688","BK1583","BK1574","LU1969619763.USD","01877","LU2328871848.SGD","BK1161"],"gpt_icon":0},{"id":"2589369893","title":"创新药的叙事经济学：叙事即估值","url":"https://stock-news.laohu8.com/highlight/detail?id=2589369893","media":"研究进化论","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589369893?lang=zh_cn&edition=full","pubTime":"2025-12-05 13:26","pubTimestamp":1764912419,"startTime":"0","endTime":"0","summary":"本文从叙事经济学角度来回答这些问题，谈谈估值和策略。这就是创新药估值的极大不确定性，在一个非常宽泛的范围里面波动。创新药行业也有很多叙事，而且由于管线关键节点之间的巨大信息真空期，提供给了叙事情绪很大的发挥空间，而不同的叙事会直接作用到上述DCF模型的各个因子上进而催动估值的大范围波动，对于这些叙事的跟踪和理解就成为了估值的一部分。特别是现在创新药行业大部分贡献估值的管线都还处在未成药的临床阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251205135245a7253773&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251205135245a7253773&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09688","LU2488822045.USD","09926","BK1161","06978","BK1574","BK1588","06855","06160","01276"],"gpt_icon":0},{"id":"2589402852","title":"【券商聚焦】交银国际：医药行业短期催化剂充足 长期继续看好创新主线","url":"https://stock-news.laohu8.com/highlight/detail?id=2589402852","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589402852?lang=zh_cn&edition=full","pubTime":"2025-12-05 10:38","pubTimestamp":1764902337,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际表示，2025年10月以来，内资通过港股通持有医药股的比例小幅下降，外资持仓从年中起亦呈回落态势，但内外资加大创新药布局的大方向不变。而外资则更积极，聚焦创新主线中的龙头及产业链上游，包括恒瑞医药、君实生物和荣昌生物等创新药，及康龙化成、药明康德和泰格医药等CXO标的。12月，行业仍有充足催化剂，包括各项学术大会、医保谈判结果公布、美联储潜在降息等，板块投资情绪有望稳中有升。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1970976","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1141","BK1161","01789","03933","HK0000165453.HKD","LU0348766576.USD","LU1969619763.USD","LU0540923850.HKD","BK1583","09926","LU2476274308.USD","BK1593","BK1617","LU0417516738.SGD","LU0348827113.USD","LU0634319403.HKD","LU2488822045.USD","IE00B543WZ88.USD","LU0417516902.SGD","BK1147","IE00BPRC5H50.USD","LU2328871848.SGD","LU0561508036.HKD","LU1770034418.SGD","BK1197","LU0348825331.USD","LU0640798160.USD","09688","02268","SG9999004311.SGD","LU1794554557.SGD","02196","01099","06160","02367","LU2778985437.USD","BK1500","LU2399975544.HKD","LU1251922891.USD","LU2476274720.SGD","BK1585","BK1588","LU0417516571.SGD","IE00B5MMRT66.SGD","01530","LU1303224171.USD","02228","LU0588546209.SGD","SG9999014674.SGD","03329"],"gpt_icon":1},{"id":"1196262606","title":"再鼎医药（9688）公布2025年11月股份变动月报：股本新增2,000,000股","url":"https://stock-news.laohu8.com/highlight/detail?id=1196262606","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1196262606?lang=zh_cn&edition=full","pubTime":"2025-12-04 19:46","pubTimestamp":1764848775,"startTime":"0","endTime":"0","summary":"再鼎医药有限公司于2025年12月4日发布截至2025年11月30日的股份变动月报。报告显示，公司法定股本维持在50亿股不变。在期权及股权激励方面，2025年11月共行使2,250股来自2022年股权激励计划的期权，皆以公司现有已发行股份结算。另根据2024年股权激励计划，当月新授出721,000股RSU，并由公司发行为奖委托人持有的2,000,000股新股。截至2025年11月底，公司总发行股份数为1,119,628,030股。该份月报由董事杜瑩签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688"],"gpt_icon":0},{"id":"2589861921","title":"每日卖空追踪 | 再鼎医药 12月04日卖空量成交37.71万股，卖空比例为4.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2589861921","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589861921?lang=zh_cn&edition=full","pubTime":"2025-12-04 16:30","pubTimestamp":1764837041,"startTime":"0","endTime":"0","summary":"再鼎医药北京时间12月04日，涨3.29%，卖空量成交37.71万股，较上一交易日减少76.13%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251204163631a4cc38d3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251204163631a4cc38d3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1588","09688","LU2488822045.USD","BK1161"],"gpt_icon":0},{"id":"2589861904","title":"再鼎医药12月04日获主力加仓367.0万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2589861904","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589861904?lang=zh_cn&edition=full","pubTime":"2025-12-04 16:15","pubTimestamp":1764836143,"startTime":"0","endTime":"0","summary":"12月04日, 再鼎医药股价涨3.29%，报收15.68元，成交金额1.2亿元，换手率0.71%，振幅3.29%，量比1.06。再鼎医药今日主力资金净流入367.0万元，连续6日净流入，上一交易日主力净流入245.2万元。近一年数据显示，该股主力连续6日净流入后，次日上涨概率为28.57%，平均涨幅为2.50%。该股近5个交易日上涨0.58%，主力资金累计净流入999.3万元，其中3个交易日为股价下跌时净流入；近20日主力资金累计净流入1.5亿元，其中净流入天数为16日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251204161925978f7f19&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251204161925978f7f19&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1161","09688","LU2488822045.USD","BK1588"],"gpt_icon":0},{"id":"2588082048","title":"再鼎医药(09688)授出购股权及受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2588082048","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588082048?lang=zh_cn&edition=full","pubTime":"2025-12-03 19:36","pubTimestamp":1764761787,"startTime":"0","endTime":"0","summary":"智通财经APP讯，再鼎医药(09688)发布公告，于2025年12月1日(美国东部时间)，本公司根据2024年股权激励计划向3名承授人授出可认购合共11,800股美国存托股份的购股权并向6名承授人涉及合共22,665股美国存托股份的受限制股份单位。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377221.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4526","ZLAB","BK4531","BK4585","BK4588","BK1161","LU2488822045.USD","BK1574","09688","BK4548","BK1588","BK4139"],"gpt_icon":0},{"id":"2588019664","title":"智通港股52周新高、新低统计|12月3日","url":"https://stock-news.laohu8.com/highlight/detail?id=2588019664","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588019664?lang=zh_cn&edition=full","pubTime":"2025-12-03 16:40","pubTimestamp":1764751201,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，截止12月3日收盘，有47只股票创52周新高，其中旅橙文化、滉达富控股、云迹创高率位于前3位，分别为29.58%、12.72%、12.41%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377040.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00213","06616","01119","09956","00363","00517","06626","02477","02587","00204","06980","01208","01397","02579","01380","00765","08627","01341","00550","00115","01451","02431","02405","00598","00215","01044","06960","01107","00693","01274","00341","01146","01268","01348","01842","09688","09878","02276","06603","02670","01373","01258","02443","02650","00412","00513","00548","01176","00300"],"gpt_icon":1},{"id":"2588042401","title":"蒸发千亿市值，器械巨头再次换帅","url":"https://stock-news.laohu8.com/highlight/detail?id=2588042401","media":"CHC医疗传媒","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588042401?lang=zh_cn&edition=full","pubTime":"2025-12-03 15:01","pubTimestamp":1764745299,"startTime":"0","endTime":"0","summary":"此次走马上任的新帅是公司老人。值得注意的是，这已是Novocure约一年内的第二次换帅。2011年，首款经FDA批准的肿瘤电场治疗设备Optune上市，是其重要里程碑。2018年9月，再鼎医药与Novocure达成协议，获得了其肿瘤电场疗法Optune的大中华区权益。2020年，再鼎医疗市值翻倍，Optune成为该公司第二大管线，净收入增长300%。患者在使用前需剃头，将贴片贴在头皮上对准肿瘤位置，在治疗期间定期更换贴片。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251203185050a7215a03&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251203185050a7215a03&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09688","LU2488822045.USD","BK1588","BK1574"],"gpt_icon":0},{"id":"2588532060","title":"每日卖空追踪 | 再鼎医药 12月02日卖空量成交53.92万股，卖空比例为6.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588532060","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588532060?lang=zh_cn&edition=full","pubTime":"2025-12-02 16:30","pubTimestamp":1764664238,"startTime":"0","endTime":"0","summary":"再鼎医药北京时间12月02日，跌2.74%，卖空量成交53.92万股，较上一交易日减少12.81%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251202163610978b665b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251202163610978b665b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1588","09688","LU2488822045.USD","BK1161"],"gpt_icon":0},{"id":"2586826477","title":"每日卖空追踪 | 再鼎医药 11月26日卖空量成交72.63万股，卖空比例为8.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586826477","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586826477?lang=zh_cn&edition=full","pubTime":"2025-11-26 16:30","pubTimestamp":1764145837,"startTime":"0","endTime":"0","summary":"再鼎医药北京时间11月26日，涨0.07%，卖空量成交72.63万股，较上一交易日减少52%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251126163616951b4c77&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251126163616951b4c77&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09688","BK1588","BK1574","LU2488822045.USD","BK1161"],"gpt_icon":0},{"id":"2585113602","title":"智通港股52周新高、新低统计|11月21日","url":"https://stock-news.laohu8.com/highlight/detail?id=2585113602","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585113602?lang=zh_cn&edition=full","pubTime":"2025-11-21 16:40","pubTimestamp":1763714401,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，截止11月21日收盘，有14只股票创52周新高，其中恒发光学、朝威控股、木薯资源创高率位于前3位，分别为42.11%、30.56%、22.49%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1372064.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02515","06960","06603","02591","00848","08500","02453","02535","02011","01119","01029","01121","00325","00040","00500","02246","01745","01268","00397","02431","01498","01274","01865","02367","00917","00610","01653","09878","00599","00841","00638","00182","09688","02587","02543","01855","01304","02818","06687","00314","00180","02508","00341","01773","01004","01134","01830","00699","03880"],"gpt_icon":1},{"id":"2585014897","title":"每日卖空追踪 | 再鼎医药 11月21日卖空量成交102.38万股，卖空比例为9.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585014897","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585014897?lang=zh_cn&edition=full","pubTime":"2025-11-21 16:30","pubTimestamp":1763713840,"startTime":"0","endTime":"0","summary":"再鼎医药北京时间11月21日，跌4.54%，卖空量成交102.38万股，较上一交易日减少46.66%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251121163618a708971b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251121163618a708971b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2488822045.USD","BK1161","BK1588","BK1574","09688"],"gpt_icon":0},{"id":"2585118598","title":"再鼎医药11月21日遭主力抛售57.3万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2585118598","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585118598?lang=zh_cn&edition=full","pubTime":"2025-11-21 16:15","pubTimestamp":1763712920,"startTime":"0","endTime":"0","summary":"11月21日, 再鼎医药股价跌4.54%，报收15.35元，成交金额1.6亿元，换手率0.95%，振幅2.99%，量比0.97。该股近5个交易日下跌10.29%，主力资金累计净流入419.1万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流入2.2亿元，其中净流入天数为14日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251121161616a7088920&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251121161616a7088920&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","09688","LU2488822045.USD","BK1588","BK1161"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.zailaboratory.com","stockEarnings":[{"period":"1week","weight":-0.0813},{"period":"1month","weight":-0.1946},{"period":"3month","weight":-0.4519},{"period":"6month","weight":-0.5321},{"period":"1year","weight":-0.3294},{"period":"ytd","weight":-0.3407}],"compareEarnings":[{"period":"1week","weight":-0.0053},{"period":"1month","weight":-0.0533},{"period":"3month","weight":-0.0306},{"period":"6month","weight":0.0809},{"period":"1year","weight":0.2833},{"period":"ytd","weight":0.2776}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"再鼎医药有限公司是一家主要从事生物制药的控股公司。该公司致力于通过产品的发现、开发和商业化解决肿瘤、自身免疫疾病、感染性疾病和中枢神经系统疾病领域未被满足的医疗需求。该公司拥有从发现阶段到临床项目后期的一系列专利候选药物。其中包括“则乐”、“OPTUNE”、“擎乐”、“纽再乐”及“卫伟迦”等。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.013207},{"month":2,"riseRate":0.6,"avgChangeRate":0.053227},{"month":3,"riseRate":0.2,"avgChangeRate":-0.100669},{"month":4,"riseRate":0.6,"avgChangeRate":0.032813},{"month":5,"riseRate":0.4,"avgChangeRate":-0.024133},{"month":6,"riseRate":0.4,"avgChangeRate":-0.013792},{"month":7,"riseRate":0.8,"avgChangeRate":0.065752},{"month":8,"riseRate":0.6,"avgChangeRate":-0.021717},{"month":9,"riseRate":0.4,"avgChangeRate":-0.054178},{"month":10,"riseRate":0.5,"avgChangeRate":-0.051338},{"month":11,"riseRate":0.5,"avgChangeRate":0.047251},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.017633}],"exchange":"SEHK","name":"再鼎医药","nameEN":"ZAI LAB"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"再鼎医药(09688)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供再鼎医药(09688)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"再鼎医药,09688,再鼎医药股票,再鼎医药股票老虎,再鼎医药股票老虎国际,再鼎医药行情,再鼎医药股票行情,再鼎医药股价,再鼎医药股市,再鼎医药股票价格,再鼎医药股票交易,再鼎医药股票购买,再鼎医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"再鼎医药(09688)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供再鼎医药(09688)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}